Phase 1 Colorectal Cancer Trial, Recruiting NCT07107230 Sponsor: Janssen Research & Development, LLC Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 1 Colorectal Cancer Trial, Recruiting

NCT07107230
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have previously been diagnosed with a confirmed form of one of these cancers that cannot be surgically removed, has spread locally, or has spread to other parts of the body: non-small cell lung cancer, colorectal cancer, or head and neck squamous cell carcinoma
  • People with non-small cell lung cancer (adenocarcinoma type) or colorectal cancer who have had specific genetic testing done on their tumour to look for certain gene changes (EGFR for lung cancer; KRAS/NRAS/BRAF for colorectal cancer)
  • People whose cancer can be measured or detected on scans — for the second part of the trial, at least one tumour must be measurable using standard criteria called RECIST v1.1 (confirm with trial site)
  • People who are relatively well and able to carry out daily activities, as measured by a standard scale called the ECOG performance status score of 0 or 1
  • People whose blood test results show that their blood, kidneys, and liver are functioning within the required ranges for this trial

Who may not be able to join:

  • People with a past history of a lung condition called interstitial lung disease (ILD) or pneumonitis, including cases caused by certain cancer immunotherapy drugs or radiation that needed steroid treatment
  • People who are still experiencing side effects from previous cancer treatment that have not improved to a mild level (Grade 1 or lower)
  • People who have had a significant active infection — viral, bacterial, or fungal — requiring treatment (other than creams or topical medicines) within the 7 days before the first dose of the trial treatment
  • People who have had a significant heart or blood vessel condition within the 6 months before signing the consent form for this trial
  • People with a history of a second, separate cancer, if that cancer or its treatment is likely to interfere with measuring how safe or effective this trial's treatment is (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
15 July 2025
Est. completion
18 November 2027

Where this trial is recruiting

🇰🇷 South Korea 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Participants with Adverse Events (AEs) by Severity; Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov